BMS Advances Cardiovascular Growth Plans With Milvexian, Camzyos Milestones

 
• By Mandy Jackson
  
Generate a summary of this article
Listen to this article
Beta

Bristol and Janssen detailed the now under way Phase III program for Factor XIa inhibitor milvexian and BMS shared data at ACC to help prescribers get comfortable with Camzyos, launched last year.

Human heart anatomy form lines and triangles, point connecting network on blue background.
Camzyos launched last year; milvexian is entering Phase III • Source: Shutterstock

Bristol Myers Squibb Company has targeted cardiovascular disease as an important therapeutic area for expansion as it looks for new launches to diversify its commercial portfolio as its top sellers face generic and biosimilar competition. And, with recent milestones for its Factor XIa inhibitor milvexian and newly launched Camzyos (mavacamten), that part of the company’s growth strategy seems to be on track.

BMS and its milvexian development partner, the Janssen Pharmaceutical Cos. of Johnson & Johnson, have initiated a massive...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

  • Sciwind Eyes Differentiation For Ecnoglutide In Highly Competitive Arena

     
    • By Xu Hu

    Chinese firm Sciwind has revealed additional Phase III findings for its promising once-weekly GLP-1 agonist ecnoglutide, just one asset in a burgeoning Chinese sector that could see the emergence of new rivals to current global leaders in obesity and diabetes.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

     
    • By Xu Hu

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

  • Sponsored By:

    Nancy Tests SPARC-931-part

    The article discusses the impact of upcoming patent expirations in oncology biologics on biosimilar developers, highlighting the opportunities in Antibody-Drug Conjugates (ADCs) and Bispecific Antibodies (BsAbs). It explores the challenges posed by the structural complexities of these biologics, necessitating new bioanalytical tools and manufacturing processes. The evolving regulatory landscape, with contributions from EMA, FDA, and WHO, offers flexible pathways but also presents challenges. The article underscores the potential for biosimilars to generate significant cost savings and enhance patient access to cancer treatments over the next decade.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

More from R&D